Back to search results

Alopecia Areata (Hair Loss)

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata (Hair Loss)

JAHO | {{ defaultRegistry.registryAnchorText }} NCT03570749 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.

Time Commitment

The study will last about 104 weeks and may include up to 18 visits.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria


Male Female


18 years
70 years
  • Participants must be at least 18 years and ≤60 years for males (≤70 years of age for females)
  • Participants must have severe or very severe alopecia areata (AA), as determined by all of the following:
    • current AA episode of more than 6 months' duration and hair loss encompassing at least half of the scalp
    • no spontaneous improvement in previous 6 months
    • current episode of severe to very severe alopecia areata of less than 8 years - current episode may be present for more than 8 years provided episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years
  • Participants must be male or nonpregnant, nonbreastfeeding female participants
  • Participants must not have primarily “diffuse” type of alopecia areata
  • Participants must not be currently experiencing other forms of alopecia or any other health problem that would make it difficult to see how the study drug is working on alopecia areata
  • Participants must not have been treated with a Janus kinase (JAK) inhibitor
    • Participants must not have topical applied to scalp within 4 weeks of randomization
    • Participants must not have oral within 8 weeks of randomization
    • Participants must not have previous inadequate response to oral JAKi (for example, absence of significant terminal hair growth after at least 12 weeks of treatment)

Where to Participate

Where to Participate

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
{{site.siteStatus | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.